SCHEMBL1934028

SCHEMBL1934028

O=Cc1cnn2c(NC3CC3)cc(NC(=O)C3CC3)nc12

nearest known ligand 0.71

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CSNK2B P67870 5/20 0.71
CSNK2A2 P19784 7/20 0.43
CSNK2A1 P68400 6/20 0.43
KCNH2 Q12809 7/20 0.41
HIPK2 Q9H2X6 2/20 0.41
HIPK1 Q86Z02 1/20 0.41
DYRK2 Q92630 1/20 0.41
HIPK3 Q9H422 1/20 0.41
STK17A Q9UEE5 1/20 0.41
DYRK3 O43781 1/20 0.41
CDK2 P24941 1/20 0.41
GSK3B P49841 1/20 0.41
PIM3 Q86V86 1/20 0.41
TYK2 P29597 3/20 0.40
PDE4D Q08499 1/20 0.37
BCL6 P41182 2/20 0.37
HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1935407 0.86 CSNK2B (0.68) CSNK2BCSNK2A2CSNK2A1KCNH2HIPK2
SCHEMBL14242544 0.84 CSNK2B (0.51) CSNK2BCSNK2A2CSNK2A1KCNH2HIPK2
SCHEMBL1934608 0.83 CSNK2B (1.00) CSNK2BCSNK2A2CSNK2A1KCNH2CDK2
SCHEMBL2028544 0.82 CSNK2B (0.48) CSNK2BCSNK2A2CSNK2A1KCNH2HIPK2
SCHEMBL2028547 0.82 CSNK2B (0.48) CSNK2BCSNK2A2CSNK2A1KCNH2HIPK2
SCHEMBL1933706 0.80 CSNK2B (0.60) CSNK2BCSNK2A2CSNK2A1KCNH2HIPK2
SCHEMBL17655144 0.80 CSNK2B (0.47) CSNK2BCSNK2A2CSNK2A1KCNH2HIPK2
SCHEMBL2033022 0.80 CSNK2B (0.59) CSNK2BCSNK2A2CSNK2A1KCNH2HIPK2
SCHEMBL2028655 0.78 CSNK2B (0.69) CSNK2BCSNK2A2CSNK2A1CDK2BCL6
SCHEMBL1486064 0.78 CSNK2B (0.69) CSNK2BCSNK2A2CSNK2A1HIPK2HIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2509602-B9 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS SENHWA BIOSCIENCES INC (TW) 2017-11-01 EP disclosed
EP-2509602-B1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS SENHWA BIOSCIENCES INC (TW) 2017-01-25 EP disclosed
US-9303033-B2 Pyrazolopyrimidines and related heterocycles as CK2 inhibitors SENHWA BIOSCIENCES, INC. (TW) 2016-04-05 US disclosed
US-8575177-B2 Pyrazolopyrimidines and related heterocycles as CK2 inhibitors SENHWA BIOSCIENCES, INC. (TW) 2013-11-05 US disclosed
US-20110152240-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2011-06-23 US disclosed
WO-2011068667-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2011-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152240-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS CDK2, CKS2, CSNK2A1 CSNK2B 13/4885CSNK2A2 5/4885CSNK2A1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.